NASDAQ:TCDA Tricida - TCDA Stock Forecast, Price & News Notice: This company has been marked as potentially delisted and may not be actively trading. Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat Daily Premium to add more stocks to your watchlist. Adding Tricida, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Add Compare Share Share Today's Range$0.09▼$0.1250-Day Range$0.11▼$0.1952-Week Range$0.09▼$13.85Volume31.13 million shsAverage Volume17.62 million shsMarket Capitalization$6.01 millionP/E RatioN/ADividend YieldN/APrice Target$17.00 ProfileAnalyst RatingsEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesSEC FilingsShort InterestSocial MediaSustainability Tricida MarketRank™ ForecastAnalyst RatingHold2.00 Rating ScoreUpside/Downside15,640.7% Upside$17.00 Price TargetShort InterestN/ADividend StrengthN/ASustainability-0.90Upright™ Environmental ScoreNews SentimentN/AInsider TradingN/AProj. Earnings GrowthGrowingFrom ($2.04) to ($1.15) Per ShareSee Full Details Hide Full Details Overall MarketRank™MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.1.84 out of 5 stars 3.0 Analyst's Opinion Consensus RatingTricida has received a consensus rating of Hold. The company's average rating score is 2.00, and is based on 1 buy rating, 3 hold ratings, and 1 sell rating.Price Target Upside/DownsideAccording to analysts' consensus price target of $17.00, Tricida has a forecasted upside of 15,640.7% from its current price of $0.11.Amount of Analyst CoverageTricida has received no research coverage in the past 90 days. Previous Next N/A Short Interest Short InterestThere is no current short interest data available for TCDA. Previous Next 0.0 Dividend Strength Dividend YieldTricida does not currently pay a dividend.Dividend GrowthTricida does not have a long track record of dividend growth. Previous Next 4.6 Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreTricida has received a 72.87% net impact score from Upright. The largest positive contribution comes from its "Physical diseases" impact, which is driven by its "Clinical research services for physiological diseases " product. See details.Environmental SustainabilityThe Environmental Impact score for Tricida is -0.90. Previous Next 0.0 News and Social Media Coverage MarketBeat FollowsOnly 2 people have added Tricida to their MarketBeat watchlist in the last 30 days. This is a decrease of -60% compared to the previous 30 days. Previous Next 1.7 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Tricida insiders have not sold or bought any company stock.Percentage Held by Insiders35.60% of the stock of Tricida is held by insiders. A high percentage of insider ownership can be a sign of company health. Previous Next 0.6 Earnings and Valuation Earnings GrowthEarnings for Tricida are expected to grow in the coming year, from ($2.04) to ($1.15) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Tricida is -0.05, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Tricida is -0.05, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings. Previous Next See Top Rated MarketRank™ Stocks Here About Tricida (NASDAQ:TCDA) StockTricida, Inc. is a pharmaceutical company. It focuses on the development and commercialization of its product, TRC101, a non-absorbed, orally-administered polymer drug designed to treat metabolic acidosis in patients with chronic kidney disease. The company was founded by Gerrit Klaerner and Craig Jon Hawker on May 22, 2013 and is headquartered in South San Francisco, CA.Read More Receive TCDA Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Tricida and its competitors with MarketBeat's FREE daily newsletter. Email Address TCDA Stock News HeadlinesFebruary 14, 2023 | finance.yahoo.comTricida, Inc. (TCDA) Stock Historical Prices & Data - Yahoo FinanceFebruary 3, 2023 | wsj.comFirm Retention Summary: Tricida Inc.March 28, 2023 | Legacy Research (Affiliate) (Ad)"Prepare for Five Years of Famine"Market Wizard who predicted all indexes would be negative in 2022 shares shocking new forecastNovember 15, 2022 | finance.yahoo.comTricida Announces Third Quarter 2022 Financial ResultsNovember 2, 2022 | finance.yahoo.comTricida Provides Strategic UpdateOctober 25, 2022 | markets.businessinsider.comWhy Tricida Stock Is Tanking TodayOctober 25, 2022 | bizjournals.comFailed trial sends Peninsula kidney drug company's stock tumbling 94%October 25, 2022 | msn.comThis Biotech Lost 95% in a Single Day. It Still Deserves CreditMarch 28, 2023 | Legacy Research (Affiliate) (Ad)"Prepare for Five Years of Famine"Market Wizard who predicted all indexes would be negative in 2022 shares shocking new forecastOctober 25, 2022 | finance.yahoo.comTricida Shares Nosedive After Disappointing Data From Much Anticipated Kidney Disease TrialOctober 24, 2022 | investorplace.comWhy Is Tricida (TCDA) Stock Down 90% Today?October 24, 2022 | finance.yahoo.comTricida Reports Topline Results from the VALOR-CKD Phase 3 Trial of VeverimerOctober 19, 2022 | seekingalpha.comTricida announces $125M debt facility - Seeking AlphaOctober 19, 2022 | seekingalpha.comTricida enters $125M debt facility (NASDAQ:TCDA) - Seeking AlphaOctober 19, 2022 | benzinga.comTricida Whale Trades For October 19 - Tricida (NASDAQ:TCDA) - BenzingaOctober 19, 2022 | businesswire.comTricida Announces $125 Million Debt Facility with Hercules Capital - Business WireOctober 18, 2022 | benzinga.com$2 Million Bet On Tricida? 3 Stocks Insiders Are Buying - Tricida (NASDAQ:TCDA), Riley Exploration Permia - BenzingaOctober 14, 2022 | businesswire.comSHAREHOLDER ALERT: Kaskela Law LLC Announces Investigation of Tricida, Inc. (TCDA) and Encourages Long-Term TCDA Stockholders to Contact the Firm - Business WireOctober 13, 2022 | benzinga.comSHAREHOLDER ALERT: Kaskela Law LLC Announces Investigation of Tricida, Inc. (TCDA) and Encourages Long-Te - BenzingaOctober 7, 2022 | benzinga.comTricida Whale Trades SpottedOctober 4, 2022 | uk.investing.com$17 Million Bet On This Technology Stock? 3 Stocks Insiders Are Buying By Benzinga - Investing.com UKOctober 3, 2022 | finance.yahoo.comTricida Announces the Selection of the VALOR-CKD Trial for an Oral Presentation in the High-Impact Clinical Trials Session at ASN Kidney Week 2022October 3, 2022 | businesswire.comTricida Announces the Selection of the VALOR-CKD Trial for an Oral Presentation in the High-Impact Clinical Trials Session at ASN Kidney Week 2022 - Business WireSeptember 29, 2022 | uk.investing.comOver $352 Million Bet On Occidental Petroleum? 3 Stocks Insiders Are Buying By Benzinga - Investing.com UKSeptember 27, 2022 | benzinga.com6TCDA : Tricida Whale Trades SpottedSeptember 24, 2022 | benzinga.comTRICIDA INVESTIGATION CONTINUED By Former Louisiana Attorney General: Kahn Swick & Foti, LLC Continues to - BenzingaSeptember 21, 2022 | seekingalpha.comTricida: Important Binary Event Coming Up (NASDAQ:TCDA) - Seeking AlphaSee More Headlines Receive TCDA Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Tricida and its competitors with MarketBeat's FREE daily newsletter. Email Address TCDA Company Calendar Last Earnings11/08/2021Today3/28/2023Next Earnings (Estimated)4/04/2023Fiscal Year End12/31/2023Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ Industry Pharmaceutical preparations Sub-IndustryN/A SectorMedical Current SymbolNASDAQ:TCDA CUSIPN/A CIK1595585 Webwww.tricida.com Phone(415) 429-7800FaxN/AEmployees57Year FoundedN/APrice Target and Rating Average Stock Price Forecast$17.00 High Stock Price Forecast$18.00 Low Stock Price Forecast$16.00 Forecasted Upside/Downside+15,640.7%Consensus RatingHold Rating Score (0-4)2.00 Research Coverage5 Analysts Profitability EPS (Most Recent Fiscal Year)($2.36) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-176,570,000.00 Net MarginsN/A Pretax MarginN/A Return on EquityN/A Return on Assets-103.81% Debt Debt-to-Equity RatioN/A Current Ratio4.87 Quick Ratio4.87 Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book ValueN/A Price / BookN/AMiscellaneous Outstanding Shares55,670,000Free Float35,851,000Market Cap$6.01 million OptionableNot Optionable Beta0.22 Key ExecutivesGerrit KlaernerPresident, Chief Executive Officer & DirectorGeoffrey M. ParkerChief Operating & Financial Officer, Executive VPDawn ParsellExecutive Vice President-Clinical DevelopmentRobert McKagueChief Compliance Officer, EVP & General CounselAnnie YoshiyamaChief Accounting Officer & Vice President-FinanceKey CompetitorsArtelo BiosciencesNASDAQ:ARTLPhio PharmaceuticalsNASDAQ:PHIOBenitec BiopharmaNASDAQ:BNTCGuardion Health SciencesNASDAQ:GHSITimber PharmaceuticalsNYSE:TMBRView All CompetitorsInsiders & InstitutionsAlliancebernstein L.P.Bought 197,300 shares on 2/16/2023Ownership: 0.386%Millennium Management LLCBought 1,027,010 shares on 2/15/2023Ownership: 1.917%Morgan StanleyBought 155,422 shares on 2/15/2023Ownership: 0.720%Belvedere Trading LLCBought 400 shares on 2/15/2023Ownership: 0.000%Jane Street Group LLCSold 112,200 shares on 2/15/2023Ownership: 0.000%View All Insider TransactionsView All Institutional Transactions TCDA Stock - Frequently Asked Questions Should I buy or sell Tricida stock right now? 5 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Tricida in the last twelve months. There are currently 1 sell rating, 3 hold ratings and 1 buy rating for the stock. The consensus among Wall Street equities research analysts is that investors should "hold" TCDA shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in TCDA, but not buy additional shares or sell existing shares. View TCDA analyst ratings or view top-rated stocks. What is Tricida's stock price forecast for 2023? 5 analysts have issued 1-year target prices for Tricida's shares. Their TCDA share price forecasts range from $16.00 to $18.00. On average, they expect the company's share price to reach $17.00 in the next year. This suggests a possible upside of 15,640.7% from the stock's current price. View analysts price targets for TCDA or view top-rated stocks among Wall Street analysts. When is Tricida's next earnings date? The company is scheduled to release its next quarterly earnings announcement on Tuesday, April 4th 2023. View our TCDA earnings forecast. How were Tricida's earnings last quarter? Tricida, Inc. (NASDAQ:TCDA) announced its quarterly earnings data on Monday, November, 8th. The company reported ($0.79) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.70) by $0.09. During the same quarter last year, the firm posted ($1.55) EPS. What is Gerrit Klaerner's approval rating as Tricida's CEO? 2 employees have rated Tricida Chief Executive Officer Gerrit Klaerner on Glassdoor.com. Gerrit Klaerner has an approval rating of 100% among the company's employees. This puts Gerrit Klaerner in the top 10% of approval ratings compared to other CEOs of publicly-traded companies. What other stocks do shareholders of Tricida own? Based on aggregate information from My MarketBeat watchlists, some companies that other Tricida investors own include Pfizer (PFE), Sorrento Therapeutics (SRNE), Gilead Sciences (GILD), Dynavax Technologies (DVAX), VBI Vaccines (VBIV), Aldeyra Therapeutics (ALDX), Atara Biotherapeutics (ATRA), bluebird bio (BLUE), Moderna (MRNA) and AT&T (T). When did Tricida IPO? (TCDA) raised $175 million in an IPO on Thursday, June 28th 2018. The company issued 10,300,000 shares at $16.00-$18.00 per share. Goldman Sachs, J.P. Morgan and Cowen acted as the underwriters for the IPO. What is Tricida's stock symbol? Tricida trades on the NASDAQ under the ticker symbol "TCDA." Who are Tricida's major shareholders? Tricida's stock is owned by a number of retail and institutional investors. Top institutional investors include Millennium Management LLC (1.92%), Two Sigma Investments LP (1.90%), Morgan Stanley (0.72%), HRT Financial LP (0.52%), UBS Group AG (0.49%) and Renaissance Technologies LLC (0.43%). Insiders that own company stock include Brian M Isern, Dawn Parsell Otto, Geoffrey M Parker, Gerrit Klaerner, Kurtis R Kurimsky, Orbimed Advisors Llc, Robert J Alpern, Robert Mckague, Sandra I Coufal and Venrock Healthcare Capital Par. View institutional ownership trends. What is Tricida's stock price today? One share of TCDA stock can currently be purchased for approximately $0.11. How much money does Tricida make? Tricida (NASDAQ:TCDA) has a market capitalization of $6.01 million. The company earns $-176,570,000.00 in net income (profit) each year or ($2.36) on an earnings per share basis. How can I contact Tricida? Tricida's mailing address is 7000 SHORELINE COURT SUITE 201, SOUTH SAN FRANCISCO CA, 94080. The official website for the company is www.tricida.com. The company can be reached via phone at (415) 429-7800 or via email at ir@tricida.com. This page (NASDAQ:TCDA) was last updated on 3/28/2023 by MarketBeat.com Staff Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.